PTC Therapeutics Files 8-K
Ticker: PTCT · Form: 8-K · Filed: Aug 19, 2025 · CIK: 1070081
Sentiment: neutral
Topics: 8-k, disclosure, financials
Related Tickers: PTC
TL;DR
PTC Therapeutics filed a standard 8-K, no major news.
AI Summary
On August 19, 2025, PTC Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits, indicating routine corporate reporting rather than a specific material event. No new financial figures or significant business updates were detailed in the provided excerpt.
Why It Matters
This filing indicates routine corporate disclosures and financial reporting by PTC Therapeutics, Inc. to the SEC.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report for disclosures and exhibits, not indicating any immediate material changes or risks.
Key Players & Entities
- PTC THERAPEUTICS, INC. (company) — Filer
- August 19, 2025 (date) — Date of earliest event reported
- 0001070081 (company) — Central Index Key
- 2834 (industry_code) — Standard Industrial Classification (Pharmaceutical Preparations)
- 043416587 (company) — IRS Employer Identification No.
- DE (jurisdiction) — State of Incorporation
- 500 Warren Corporate Center Drive (address) — Business Address
- Warren (city) — Business Address City
- NJ (state) — Business Address State
- 07059 (zip_code) — Business Address Zip
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing is primarily for Regulation FD Disclosure and to report Financial Statements and Exhibits.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is August 19, 2025.
What is PTC Therapeutics, Inc.'s Standard Industrial Classification code?
PTC Therapeutics, Inc.'s Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
In which state is PTC Therapeutics, Inc. incorporated?
PTC Therapeutics, Inc. is incorporated in Delaware.
What is the business address of PTC Therapeutics, Inc.?
The business address of PTC Therapeutics, Inc. is 500 Warren Corporate Center Drive, Warren, NJ 07059.
Filing Stats: 585 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2025-08-19 08:10:10
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share PTCT Nasdaq Glo
Filing Documents
- tmb-20250819x8k.htm (8-K) — 44KB
- tmb-20250819xex99d1.htm (EX-99.1) — 25KB
- 0001558370-25-011658.txt ( ) — 188KB
- tmb-20250819.xsd (EX-101.SCH) — 4KB
- tmb-20250819_def.xml (EX-101.DEF) — 3KB
- tmb-20250819_lab.xml (EX-101.LAB) — 16KB
- tmb-20250819_pre.xml (EX-101.PRE) — 9KB
- tmb-20250819x8k_htm.xml (XML) — 5KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On August 19, 2025, PTC Therapeutics, Inc. issued a press release announcing that it had received a Complete Response Letter from the U.S. Food and Drug Administration related to the New Drug Application for vatiquinone for the treatment of children and adults living with Friedreich's ataxia. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this "Report") and is incorporated by reference into this Item 7.01. The information in this Report (including Item 7.01 and Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. All website addresses given in this Report or incorporated herein by reference are for information only and are not intended to be an active link or to incorporate any website information into this Report.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated August 19, 2025 issued by PTC Therapeutics, Inc. 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. PTC Therapeutics, Inc. Date: August 19, 2025 By: /s/ Pierre Gravier Name: Pierre Gravier Title: Chief Financial Officer